A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022

Abstract

Background. Current medical management of endometriosis leads to suppression of ovulation and will not be helpful for women with endometriosis who are desirous of pregnancy. Thus, drugs that can both treat endometriosis and its associated infertility are highly warranted.

Objective. Anti-angiogenic agents are potential drugs for patients with endometriosis and infertility. Among these drugs, dopamine agonist (DA) is promising since it does not interfere with ovulation, is safe, and not teratogenic. The aim of the study is to determine the efficacy and safety of DA for improving reproductive outcomes in women with endometriosis and infertility.

Methods. A qualitative narrative review was done from inception to July 31, 2022 using the appropriate MeSH
terms in PubMed, Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials,
ClinicalTrial.gov, and World Health Organization International Clinical Trials Registry Platform. Date analysis was
through qualitative analysis and synthesis of researches and their outcome measures.

Results. No studies used the core outcomes for trials evaluating treatments for infertility associated with endometriosis. All the included articles in the review supported the possible anti-angiogenic effects of DA on the vascular endothelial growth factor [VEGF] /VEGF receptor system. The use of DA does not have an effect on ovulation and menstrual cyclicity. Studies on safety profile of DA were consistent with existing data.

Conclusion. Most of studies reviewed demonstrated that DA were effective in reducing endometriotic lesions.
However, further research is required to establish whether this anti-angiogenic effect can improve reproductive
outcomes in women with endometriosis-associated infertility.